Skip to main
BLTE
BLTE logo

BLTE Stock Forecast & Price Target

BLTE Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 60%
Buy 40%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Belite Bio Inc. is positioned for potential growth driven by upcoming updates on its tinlarebant Phase 3 programs targeting untreatable eye diseases, with increased sample sizes in trials indicating strong engagement and progress. The heightened investor interest following recent positive interim analysis results and an upward revision in both pricing estimates for tinlarebant and prevalence estimates for Stargardt disease further bolsters the company's outlook. Additionally, Belite Bio maintains a robust cash position, reflecting financial stability that supports ongoing development initiatives.

Bears say

Belite Bio Inc reported a net loss of $36.1 million in 2024, highlighting significant ongoing financial challenges that may deter investor interest. The company's pivotal trial for tinlarebant, while showing positive interim analysis for Stargardt disease, is accompanied by substantial risks, including potential failure in clinical trials, regulatory approval, and commercial viability. Additionally, concerns about dilution and stringent regulatory requirements cast further doubt on the company's financial outlook and ability to successfully bring its therapeutic products to market.

BLTE has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 60% of analysts recommend a Strong Buy, 40% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Belite Bio Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Belite Bio Inc (BLTE) Forecast

Analysts have given BLTE a Strong Buy based on their latest research and market trends.

According to 5 analysts, BLTE has a Strong Buy consensus rating as of Aug 3, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $71.60, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $71.60, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Belite Bio Inc (BLTE)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.